These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33277224)

  • 1. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
    Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
    Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
    Tun AM; Wang Y; Maliske S; Micallef I; Inwards DJ; Habermann TM; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
    Haematologica; 2024 Jul; 109(7):2186-2195. PubMed ID: 38235513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
    Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
    Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
    Kambhampati S; Hunter B; Varnavski A; Fakhri B; Kaplan L; Ai WZ; Pampaloni M; Huang CY; Martin T; Damon L; Andreadis CB
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):246-256.e2. PubMed ID: 33288485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
    Villa D; Seshadri T; Puig N; Massey C; Tsang R; Keating A; Crump M; Kuruvilla J
    Haematologica; 2012 May; 97(5):751-7. PubMed ID: 22180434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post-Autologous Stem Cell Transplant.
    Ladbury C; Kambhampati S; Othman T; Hao C; Chen L; Wong J; Cao T; Herrera A; Mei M; Dandapani S
    Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):594-601. PubMed ID: 35176414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Up-front Autologous Stem-Cell Transplantation at First Relapse Improve Outcome in Transplant-Eligible Follicular Lymphoma Patients Whose Disease Relapses Within 24 Months?
    Yahya A; Radhwi O; Sobh M; Huebsch L; MacDonald D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e423-e427. PubMed ID: 33558203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
    Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
    Kewalramani T; Zelenetz AD; Nimer SD; Portlock C; Straus D; Noy A; O'Connor O; Filippa DA; Teruya-Feldstein J; Gencarelli A; Qin J; Waxman A; Yahalom J; Moskowitz CH
    Blood; 2004 May; 103(10):3684-8. PubMed ID: 14739217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
    Gisselbrecht C; Glass B; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Ketterer N; Shpilberg O; Hagberg H; Ma D; Brière J; Moskowitz CH; Schmitz N
    J Clin Oncol; 2010 Sep; 28(27):4184-90. PubMed ID: 20660832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
    Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
    J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.
    Landsburg DJ; Nasta SD; Svoboda J; Gerson JN; Schuster SJ; Barta SK; Chong EA; Difilippo H; Weber E; Cunningham K; Catania C; Garfall AL; Stadtmauer EA; Frey NV; Porter DL
    Transplant Cell Ther; 2023 Aug; 29(8):495-503. PubMed ID: 37211154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
    Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
    Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma.
    Lisenko K; Cremer M; Schwarzbich MA; Kriegsmann M; Ho AD; Witzens-Harig M; Wuchter P
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1397-1402. PubMed ID: 27060439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.
    Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
    Future Oncol; 2019 Mar; 15(9):1021-1034. PubMed ID: 30757910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.